Calling all Organic Chem geeks…name this structure? It treats nausea!

Dr Massoomi isopropyl Alcohol

You may ask why?  Well this is C3H8O or C3H7OH or CH3CHOHCH3

It is a colorless, flammable chemical compound with a strong odor.  It is a secondary alcohol.   

Isopropyl Alcohol –  Inhalation of Isopropyl Alcohol Alleviates Nausea in ED Patients!  Well thats simple, many people have these laying around.

Dr Massoomi Isopropyl alcohol wipes

Dr. Diana Egerton-Warburton and her team performed a Randomized Controlled Trial Comparing Ondansetron (Zofran), Metoclopramide (Reglan) and Placebo.  They discovered a reductions in nausea severity for patients in the emergency room with nausea and vomiting, when compared to 4 mg IV ondansetron (Zofran), 20 mg IV metoclopramide (Reglan) and placebo.

So before you reach for ondansetron (Zofran) or metoclopramide (Reglan)…try the alcohol wipes!

Here is the actual article:

Antiemetic Use for Nausea and Vomiting in Adult Emergency Department Patients: Randomized Controlled Trial Comparing Ondansetron, Metoclopramide, and Placebo

Diana Egerton-Warburton, MBBS, FACEM; Robert Meek, MBBS, FACEM*; Michaela J. Mee, MBBS, FACEM; George Braitberg, MBBS, FACEM
*Corresponding Author. E-mail: robertmeek66@hotmail.com.

Study objective: We compare efficacy of ondansetron and metoclopramide with placebo for adults with undifferentiated emergency department (ED) nausea and vomiting.

Methods: A prospective, randomized, double-blind, placebo-controlled trial was conducted in 2 metropolitan EDs in Melbourne, Australia. Eligible patients with ED nausea and vomiting were randomized to receive 4 mg intravenous ondansetron, 20 mg intravenous metoclopramide, or saline solution placebo. Primary outcome was mean change in visual analog scale (VAS) rating of nausea severity from enrollment to 30 minutes after study drug administration. Secondary outcomes included patient satisfaction, need for rescue antiemetic treatment, and adverse events.

Results: Of 270 recruited patients, 258 (95.6%) were available for analysis. Of these patients, 87 (33.7%) received ondansetron; 88 (34.1%), metoclopramide; and 83 (32.2%), placebo. Baseline characteristics between treatment groups and recruitment site were similar. Mean decrease in VAS score was 27 mm (95% confidence interval [CI] 22 to 33 mm) for ondansetron, 28 mm (95% CI 22 to 34 mm) for metoclopramide, and 23 mm (95% CI 16 to 30 mm) for  placebo. Satisfaction with treatment was reported by 54.1% (95% CI 43.5% to 64.5%), 61.6% (95% CI 51.0% to 71.4%), and 59.5% (95% CI 48.4% to 69.9%) for ondansetron, metoclopramide, and placebo, respectively; rescue medication was required by 34.5% (95% CI 25.0% to 45.1%), 17.9% (95% CI 10.8% to 27.2%), and 36.3% (95% CI 26.3% to 47.2%), respectively. Nine minor adverse events were reported.

Conclusion: Reductions in nausea severity for this adult ED nausea and vomiting population were similar for 4 mg intravenous ondansetron, 20 mg intravenous metoclopramide, and placebo. There was a trend toward greater reductions in VAS ratings and a lesser requirement for rescue medication in the antiemetic drug groups, but differences from the placebo group did not reach significance. The majority of patients in all groups were satisfied with treatment. [Ann Emerg Med. 2014;64:526-532.]